· News · News Desk
751 vials labeled tirzepatide actually contained testosterone cypionate. Two years on, the Revive Rx Class I recall remains the most severe compounded GLP-1 safety event on record — and is still cited in FDA enforcement rationale.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.